Dolasetron | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | |
Dolasetron | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Dolasetron | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
Dolasetron | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
Dolasetron | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Dolasetron | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Dolasetron | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Dolasetron | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Dolasetron | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | |
Dolasetron | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
Dolasetron | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | |
Dolasetron | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | |
Dolasetron | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
Dolasetron | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | |
Dolasetron | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | |
Dolasetron | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Dolasetron | hsa04012 | ErbB signaling pathway | 3.15E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | |
Dolasetron | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | |
Dolasetron | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | |
Dolasetron | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | |
Dolasetron | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
Dolasetron | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | |
Dolasetron | hsa04110 | Cell cycle | 1.44E-02 | 7 | P06493, O75293, P30304, P33981, P42773, P01106, Q13547 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC, HDAC1 | More | |
Dolasetron | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Dolasetron | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | |
Dolasetron | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
Dolasetron | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | |
Dolasetron | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
Dolasetron | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
Dolasetron | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | |
Dolasetron | hsa04530 | Tight junction | 4.35E-02 | 2 | P63261, Q92974 | ACTG1, ARHGEF2 | More | |
Dolasetron | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
Dolasetron | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | |
Dolasetron | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | |
Dolasetron | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
Dolasetron | hsa04658 | Th1 and Th2 cell differentiation | 1.47E-07 | 10 | Q04759, P07766, P20963, P19174, P01730, P06239, P42224, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, CD4, LCK, STAT1, TBX21, IL2RB, RUNX3 | More | |
Dolasetron | hsa04659 | Th17 cell differentiation | 2.08E-05 | 10 | Q04759, P19174, P01730, P06239, P42224, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, CD4, LCK, STAT1, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | |
Dolasetron | hsa04660 | T cell receptor signaling pathway | 4.50E-04 | 10 | Q04759, P42338, P19174, P16333, P07766, P20963, P01730, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, NCK1, CD3E, CD247, CD4, CD8A, CBLB, LCK | More | |
Dolasetron | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Dolasetron | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Dolasetron | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
Dolasetron | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
Dolasetron | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | |
Dolasetron | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
Dolasetron | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
Dolasetron | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | |
Dolasetron | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
Dolasetron | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
Dolasetron | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Dolasetron | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
Dolasetron | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
Dolasetron | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
Dolasetron | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
Dolasetron | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | |
Dolasetron | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | |
Dolasetron | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Dolasetron | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | |
Dolasetron | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Dolasetron | hsa05223 | Non-small cell lung cancer | 4.24E-02 | 3 | P19174, Q9HC35, O75293 | PLCG1, EML4, GADD45B | More | |
Dolasetron | hsa05231 | Choline metabolism in cancer | 4.24E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | |
Dolasetron | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.41E-05 | 9 | P42338, P19174, P07766, P20963, P06239, P42224, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, LCK, STAT1, PRKCQ, EML4, CD4 | More | |
Dolasetron | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Dolasetron | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Dolasetron | hsa05340 | Primary immunodeficiency | 4.24E-02 | 3 | P01730, P07766, P06239 | CD4, CD3E, LCK | More | |
Dolasetron | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |